EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors

Greta Donati, Monica Viviano iD, Vincenzo Maria D'Amore, Alessandra Cipriano, Isidora Diakogiannaki, Jussara Amato, Stefano Tomassi, Diego Brancaccio, Pasquale Russomanno, Francesco Saverio Di Leva, Daniela Arosio, Pierfausto Seneci und 8 weitere

Archiv der Pharmazie · 2024-03 · 357 (3)

DOI: 10.1002/ardp.202300583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 18.12.2023. Verfasst von Greta Donati und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Biphenyl Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacja na rzecz Nauki Polskiej, European Regional Development Fund, Ministero dell'Istruzione, dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a game‐changing approach for cancer treatment. Although monoclonal antibodies (mAbs) targeting the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD‐1/PD‐L1) axis have entered the market revolutionizing the treatment landscape of many cancer types, small molecules, although presenting several advantages including the possibility of oral administration and/or reduced costs, struggled to enter in clinical trials, suffering of water insolubility and/or inadequate potency compared with mAbs. Thus, the search for novel scaffolds for both the design of effective small molecules and possible synergistic strategies is an ongoing field of interest. In an attempt to find novel chemotypes, a virtual screening approach was employed, resulting in the identification of new chemical entities with a certain binding capability, the most versatile of which was the benzimidazole‐containing compound 10 . Through rational design, a small library of its derivatives was synthesized and evaluated. The homogeneous time‐resolved fluorescence (HTRF) assay revealed that compound 17 shows the most potent inhibitory activity (IC 50 ) in the submicromolar range and notably, differently from the major part of PD‐L1 inhibitors, exhibits satisfactory water solubility properties. These findings highlight the potential of benzimidazole‐based compounds as novel promising candidates for PD‐L1 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorBiphenyl CompoundsB7-H1 AntigenLigandsStructure-Activity RelationshipBenzimidazolesWater

Stichwörter der Autor:innen

NMRPD-L1 inhibitorsbenzimidazoleimmunotherapyvirtual screening

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenLigandsBenzimidazolesWaterBiphenyl Compoundsbiphenyl

Autor:innen und Institutionen

  • Department of Pharmacy, University of Naples Federico II, Naples, Italy.
  • Department of Pharmacy, University of Salerno, Fisciano, Italy.
  • Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche (CNR), Milan, Italy.
  • Department of Chemistry, University of Milan, Milan, Italy.
  • Department of Pharmacy, University of Pisa, Pisa, Italy.
  • Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Cracow, Poland.

ORCID-Profile: Monica Viviano, Lukasz Skalniak

Förderung

  • Fundacja na rzecz Nauki Polskiej
  • European Regional Development Fund
  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • Italian Ministry of Education, University, and Research (MIUR)
  • Progetti di Rilevante Interesse Nazionale, PRIN 2017
  • PRIN 2022
  • POIR
  • European Union

Zitieren

APA

Donati, G., Viviano, M., D'Amore, V. M., Cipriano, A., Diakogiannaki, I., Amato, J., Tomassi, S., Brancaccio, D., Russomanno, P., Di Leva, F. S., Arosio, D., Seneci, P., Taliani, S., Magiera-Mularz, K., Musielak, B., Skalniak, L., Holak, T. A., Castellano, S., La Pietra, V., & Marinelli, L. (2024). A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors. Archiv der Pharmazie, 357(3). https://doi.org/10.1002/ardp.202300583

Vancouver

Donati G, Viviano M, D'Amore VM, Cipriano A, Diakogiannaki I, Amato J, et al. A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors. Archiv der Pharmazie. 2024;357(3). doi:10.1002/ardp.202300583

BibTeX
@article{Donati2024,
  author = {Donati, Greta and Viviano, Monica and D'Amore, Vincenzo Maria and Cipriano, Alessandra and Diakogiannaki, Isidora and Amato, Jussara and Tomassi, Stefano and Brancaccio, Diego and Russomanno, Pasquale and Di Leva, Francesco Saverio and Arosio, Daniela and Seneci, Pierfausto and Taliani, Sabrina and Magiera-Mularz, Katarzyna and Musielak, Bogdan and Skalniak, Lukasz and Holak, Tad A and Castellano, Sabrina and La Pietra, Valeria and Marinelli, Luciana},
  title = {A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors},
  journal = {Archiv der Pharmazie},
  year = {2024},
  volume = {357},
  number = {3},
  doi = {10.1002/ardp.202300583}
}
Kostenlos starten →